<DOC>
	<DOCNO>NCT00038675</DOCNO>
	<brief_summary>The goal clinical research study see Gleevec , know imatinib mesylate ( STI571 ) , improve disease condition patient hypereosinophilic syndrome , polycythemia vera , atypical CML CMML PDGF-R fusion gene , mastocytosis .</brief_summary>
	<brief_title>Therapy HES , PV , Atypical Chronic Myelocytic Leukemia ( CML ) Chronic Myelomonocytic Leukemia ( CMML ) , Mastocytosis With Imatinib Mesylate</brief_title>
	<detailed_description>Imatinib mesylate chemical compound block protein responsible certain form leukemia . However , imatinib mesylate also block important protein may responsible blood disease myeloproliferative disorder . Patients study take 4 tablet imatinib mesylate mouth every day . Patients HES take 1 tablet daily begin , may go 4 tablet daily depend response . Imatinib mesylate take morning breakfast large glass water . Bottles contain tablet give patient every month . Unused supply must return end study . Patients take oral hydroxyurea control blood count , continue first month imatinib mesylate treatment , must stop taking . After complete 2 month therapy , response imatinib mesylate evaluate . If response good , treatment imatinib mesylate alone continue . If response good , dose imatinib mesylate increase 8 tablet daily ( 4 morning 4 evening ) may decrease 3 tablet daily . This base drug tolerate . Treatment may continue one year , long judged best control leukemia . Patients ask visit doctor physical exam vital sign . The frequency doctor visit vary depend physical condition . Blood test ( 2 teaspoon ) do year . The blood sample use routine lab test . A bone marrow sample also take check measure cell related disease 3 - 4 month , every 3-6 month first year . If initial bone marrow sample show disease , repeat bone marrows do . This investigational study . Imatinib mesylate approve CML patient whose disease respond interferon . However , investigational study patient myeloproliferative disease . The FDA authorize use imatinib mesylate research . A total 145 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Pts must 1 follow hematopoietic malignancy : Hypereosinophilic syndrome ( HES ) , Polycythemia vera ( PV ) , Atypical CML CMML PDGFR fusion gene , Mastocytosis , Serum bilirubin less 2 mg % , serum creatinine le 2 mg % unless abnormality consider due hematologic malignancy investigator , Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 3 , life expectancy &gt; 12 wks , 2. continue . Pts must sign informed consent indicate aware investigational nature study , keep policy hospital , woman pregnancy potential must practice birth control . Women men must continue birth control duration trial least 3 month last dose study drug . Inclusion woman minority : As per NIH policy , woman member minority include protocol refer relevant population . 3. continue . There exclusion woman minority base study objective , New York Heart Association ( NYHA ) Class &lt; 3 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Hypereosinophilic Syndrome</keyword>
	<keyword>Mastocytosis</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
</DOC>